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for both groups. One-to-one propensity score matching (PSM) was used to compare 
health care costs and utilizations during the follow-up period between the HCV 
and comparison groups, adjusting for baseline demographic and clinical charac-
teristics. Results: Eligible patients (N= 270,752) were identified for the HCV and 
comparison cohorts. After applying 1:1 PSM matching, a total of 107,953 patients 
were matched from each group and baseline characteristics were well-balanced. 
HCV patients were more likely to be hospitalized (15.90% vs. 3.19%, p< 0.01) and 
report more emergency room (20.36% vs. 8.17%, p< 0.01), physician office (99.18% 
vs. 61.06%, p< 0.01), outpatient (99.25% vs. 61.84%, p< 0.01) and pharmacy visits 
(91.11% vs. 63.13%, p< 0.01) which resulted in higher health care costs for inpatient 
($5,284 vs. $911, p< 0.01), emergency room ($237 vs.$76, p< 0.01), outpatient ($4,673 
vs. $1,760, p< 0.01), physician office ($4,247 vs. $1,560, p< 0.01), pharmacy ($889 vs. 
$460, p< 0.01) and total costs ($10,846 vs. $3,131, p< 0.01) for HCV patients relative 
to the comparison group. ConClusions: Patients diagnosed with HCV were more 
likely to report higher health care utilization and were associated with a higher 
economic burden compared to the matched controls.
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objeCtives: : Pertussis (whooping cough) is a highly contagious bacterial disease. 
Infants in the first few months of life are particularly vulnerable with the highest 
reported rate of pertussis, risk of severe disease and deaths. Although, vaccina-
tion coverage rates have reached record-high levels in the United States (US), vac-
cine timeliness remains an issue. Methods: Using data from the 2010 National 
Immunization Survey (NIS), we estimated the vaccination timeliness for DTaP vac-
cines in US infants. A previously published static model accounted for the reduction 
of incidence of pertussis by vaccination according to a strict adherence to the ACIP 
vaccination schedule. The annual numbers of pertussis cases prevented in infants 
and the associated costs avoided from a health care system perspective were esti-
mated. Results: From the NIS dataset, the mean age at DTaP vaccination was 
76.3, 147.4 and 223.9 days, which means that on average each vaccination was in 
average delayed by 16.3, 27.4 and 43.9 days (with delays accumulating over time), 
respectively. The model predicted 3052 pertussis cases annually in infants < 1 year 
of age in the US. Applying a strict adherence to the vaccination schedule, approxi-
mately 313 cases of pertussis, 112 hospitalisations and 1 death could be avoided 
each year. This translates into savings of 57 QALYs and $1.3 million of costs to the 
health care system. ConClusions: Although previous publications have presented 
the number of cases avoided by timely vaccination, to our knowledge this is the 
first one to present the associated costs. Administering vaccines on time not only 
avoids cases but may also have a significant impact on quality of life and costs. 
These costs avoided may be redirected to developing tools and/or infrastructure to 
improve the vaccine timeliness of infants in future. Further research is needed to 
better understand the role of vaccination timeliness and completion.
PIN34
sTuDy of aNTIbIoTIc coNsumPTIoN PaTTerN IN hosPITal acquIreD 
PNeumoNIa
Kunhikatta V.1, Rau N.R.2, Naik A.N.1, Yamsani B.1, Thunga G.1, Nair S.1
1Manipal College of Pharmaceutical Sciences, Manipal University, Manipal, India, 2Kasturba 
Medical College, Manipal University, Manipal, India
objeCtives: To analyse the antibiotic consumption pattern in hospital acquired 
pneumonia (HAP) patients in a tertiary care teaching hospital Methods: A pro-
spective observational study, carried out in a tertiary care teaching hospital from 
January 2011 to December 2012. HAP patients who fulfill the inclusion criteria were 
identified and enrolled into the study after taking informed consent. Patients were 
followed from the day of diagnosis of HAP, till the day of discharge or death. Patient 
data like demography (age, sex), antimicrobial agents used (dose, duration of treat-
ment), length of hospital stay and clinical outcome were recorded in a predesigned 
data collection form. The cost of antimicrobial therapy was recorded from the day 
of admission till the day of discharge. Antibiotic consumption was calculated using 
defined daily dose (DDD) methodology. Results: Total 310 patients were included 
in the study. Among study population 229 (73.9%) patients were male and mean age 
was 55.9±18.4 (mean±SD). Out of 310 patients 218 were improved, 37 were worsened 
or discharged against medical advice and 55 were expired. Mean length of hospi-
talization was 9.45±6.75 (mean±SD) days. Total 27 antimicrobial agents were used 
for the treatment pneumonia among these patients. Among these antimicrobial 
agents, consumption (DDD/100 bed days) was highest for piperacillin-tazobactum 
(parenteral, 0.12) followed by ceftriaxone (parenteral, 0.10), azithromycin (oral, 0.10) 
and trimethoprim-sulphamethoxazole (oral, 0.08). The percentage of treatment suc-
cess was highest among patients treated with piperacillin-tazobactum+macrolide 
combination (10%) followed by cephalosopin+macrolide combination (8%). 
However the cost of treatment was high for piperacillin-tazobactum+macrolide 
regimen ConClusions: This study provides estimate of quantities of differ-
ent antimicrobial agents used in the treatment of hospital acquired pneumonia. 
Piperacillin-tazobactum (parenteral) is highest consumed among 27 antimicrobial 
agents. Since percentage of treatment success is almost similar for piperacillin-
tazobactum+macrolide combination (10%) and cephalosopin+macrolide combina-
tion (8%), use of cephalosopin+macrolide combination should be encouraged in 
susceptible patients considering the lesser cost.
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drugs in the 1st and 2d line of therapy and routine follow-up costs were calculated 
based on prices of state procurements in the framework of national project of HIV 
prevention and the tariffs of the Russian health care system in 2012. One-way sen-
sitivity analysis was performed. Results: ABC/3TC+EFV is not associated with 
more costs vs ABC + 3TC + EFV regimen and even saves approximately 3390.60 rub 
(€ 80.30) per patient over 96 weeks of treatment. The sensitivity analysis showed that 
ABC/3TC FDC remains to be cost saving compared with ABC+3TC as long as the its 
package price is less than 6564.17 rub (€ 155.46) while keeping other model param-
eters unchanged. Still ABC/3TC+EFV is 28% more expensive than ZDV/3TC+EFV, 
though more effective and safe treatment option: the difference in costs vs 
ABC/3TC+EFV is 45267.05 rub. (€ 1,072.05) per patient over 96 weeks. ConClusions: 
FDC ABC/3TC may be considered as a more efficient and convenient treatment 
option than its monocomponents combination for first-line antiretroviral therapy 
of HIV patients in Russia. FDC ABC/3TC is more expensive versus ZDV/3TC, but the 
difference in costs seems appropriate for more safe and convenient alternative.
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objeCtives: To explore new patient pathways using a chlamydia/gonorrhoea point of 
care nucleic acid amplification test (POC NAAT), and estimate and compare the costs 
of the new pathways with the current pathways using standard laboratory-based 
NAAT testing in the UK. Methods: Consensus building activities were conducted 
with four sexual health clinics in the UK. They were selected through purposeful 
sampling to reflect a wide range of service delivery. Current pathways in which a 
chlamydia/gonorrhoea test was used were mapped out, and then new pathways 
using a POC NAAT were constructed. The consensus pathways were then costed using 
a patient pathway model built in Excel, and the cost of the current and POC NAAT 
pathways compared. Results: Pathways using a POC NAAT for asymptomatic and 
symptomatic patients and chlamydia/gonorrhoea only tests were shorter and less 
expensive than most of the current pathways (average savings of £4-8 for sympto-
matic and asymptomatic screening pathways if the POC NAAT costs £18/test). Patients 
that are tested using the POC NAAT can be treated on the same day, thus saving costs 
compared to patients who are treated at a subsequent appointment. ConClusions: 
A POC NAAT could be introduced to services and reduce current costs, and may mean 
more appropriate and quicker care for positive patients.
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objeCtives: In Ukraine immunization by age conducts against 10 infectious 
diseases: tuberculosis, hepatitis B (HBV), diphtheria, pertussis, tetanus, polio, 
Haemophilus influenzae, measles, rubella, mumps .The Law of Ukraine from 
21.10.2009 N 1658-VI approved the Program of immunization and protection against 
infectious diseases during 2009-2015.During the years 2011-2012 the media incor-
rectly submitted data on the results of vaccination and many parents refused vac-
cination and as a result there were about 12,000 cases of measles and rubella, it’s 
80 times more than in previous years. On State program of vaccination in 2010 
was allocated 237 mln UAH (1 USD= 7.99 UAH), in 2011 - 237 mln, in 2012 - 302 mln 
UAH. Methods: We conducted a cost per 1,000 children aged 0 to 1 years. Direct 
costs were calculated for vaccine Pentaxim (Sanofi Pasteur) which combined vac-
cine against hepatitis B (ukrainian producer “Biolik”) and was compared the costs 
for vaccine Infanrix hexa (GSK). We included the vaccine costs, the loss during 
storage, and the costs of medical personnel for vaccination. We used the prices 
from the ukrainian electronic pricing database “MORION” on 01.06.2012. Analysis of 
evidence-based data has shown that Pentaxim is equal clinical efficacy of Infanrix 
hexa, but increases the rate of vaccination coverage against hepatitis B. Results: 
The costs for Pentaxim and HiB vaccine were 633 240 UAH and costs of medical 
personnel (pediatrics, nurses) were 36763 UAH. The costs using vaccine Infanrix 
hexa were 803880 UAH, the costs of medical personnel – 18 381 UAH, respec-
tively. ConClusions: In 2012, 385 116 children vaccinated by Infanrix hexa and 
general costs were 118 307 590 UAH vs 363 000 children by Pentaxim were 95 830 
447 UAH. The results shown the need additional 22477143 UAH, which is justified 
to increase vaccination coverage against hepatitis B by 6%.
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objeCtives: To examine the economic burden and health care utilizations of the 
hepatitis C virus (HCV) in the U.S. veteran population. Methods: A retrospec-
tive database analysis was performed using the Veterans Health Administration 
Medical SAS datasets 01OCT2008-30SEP2012). Patients diagnosed with HCV 
(International Classification of Disease 9th Revision Clinical Modification [ICD-
9-CM] codes 070.41, 070.44, 070.51, 070.54, v02.62) were identified, and the first 
diagnosis date served as the index date. A comparator group was created by iden-
tifying patients without HCV but with the same age, region, gender and index year, 
and matching them by baseline Charlson Comorbidity Index. The index date for 
the comparator group was randomly chosen to reduce selection bias. A 1-year 
continuous health plan enrollment period pre- and post-index date was required 
